Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CESAR: Esketamine nasal spray versus aripiprazole, each combined with an antidepressant, in older adults with refractory major depressive disorder
2024-512672-34-00Phase 3Authorised
- Sponsor
- Fundación Pública Andaluza para la Gestión de la Investigación
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in major depressive disorder (MDD) comparing Esketamine nasal spray plus antidepressant with Aripiprazole plus antidepressant (2 arms). Primary endpoint: Clinical response at week 8. Planned start Feb 2026; status: authorised.
02
Drugs
esketaminearipiprazole
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2024-512672-34-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512672-34-00.